CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The CCTG Annual Spring Meeting is only 6 weeks away! Don't forget that the request an invitation portal closes April 7 and online registration closes April 9.
HDC1 sub-study: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on SWOG S1826
The current CTEP website at ctep.cancer.gov was retired on July 9, 2025, and all the site information was relocated to new URLs.
2025 Q2 Planned trials
The SKC1 skin cancer clinical trial is now open to enrollment across Canada. This study aims to determine whether adding an immunotherapy drug prior to the standard surgical treatment for advanced skin cancer can improve patient outcomes. This study addresses a substantial unmet need in this patient population.
The MA33 (TROG 0701): A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast, has permanently closed.
The recently opened BR38 clinical trial is exploring whether adding stereotactic body radiotherapy (SBRT) to the current treatment of immunotherapy (with or without chemotherapy) can improve outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and limited disease progression (oligoprogression).
